EXEL vs MRNA
Exelixis, Inc. and Moderna, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | EXEL | MRNA |
|---|---|---|
| Revenue | $2.3B | $1.9B |
| Net income | $782.6M | $-2.8B |
| Gross margin | 96.4% | 55.3% |
| Net margin | 33.7% | −145.2% |
| Return on equity | 35.5% | −28.9% |
| Diluted EPS | $2.78 | −$7.26 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | $875.8M | $-2.1B |
| Equity | $2.2B | $8.7B |
| Net debt / equity | −0.66× | −0.23× |
| Current ratio | 3.56× | 3.29× |
| Revenue CAGR 5y | 18.6% | 19.3% |
| Profit CAGR 5y | 47.6% | — |
EXEL bills 1.2× the revenue of MRNA, and MRNA closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | EXEL | MRNA |
|---|---|---|
| FY2025 | $2.3B | $1.9B |
| FY2024 | $2.2B | $3.2B |
| FY2023 | $1.8B | $6.8B |
| FY2022 | $1.6B | $19.3B |
| FY2021 | $1.4B | $18.5B |
| FY2020 | $987.5M | $803.0M |
| FY2019 | $967.8M | $60.0M |
| FY2018 | $853.8M | $135.1M |
| FY2017 | $452.5M | $205.8M |
| FY2016 | $191.5M | $108.4M |
Net income by year
Bottom line
| Fiscal year | EXEL | MRNA |
|---|---|---|
| FY2025 | $782.6M | $-2.8B |
| FY2024 | $521.3M | $-3.6B |
| FY2023 | $207.8M | $-4.7B |
| FY2022 | $182.3M | $8.4B |
| FY2021 | $231.1M | $12.2B |
| FY2020 | $111.8M | $-747.0M |
| FY2019 | $321.0M | $-514.0M |
| FY2018 | $690.1M | $-384.7M |
| FY2017 | $154.2M | $-255.9M |
| FY2016 | $-70.2M | $-216.2M |
Advertisement
AdSense · Rectangle 336×280
More in this industry